Edition:
United Kingdom

MabVax Therapeutics Holdings Inc (MBVX.OQ)

MBVX.OQ on NASDAQ Stock Exchange Capital Market

1.30USD
23 May 2018
Change (% chg)

$-0.05 (-3.70%)
Prev Close
$1.35
Open
$1.26
Day's High
$1.33
Day's Low
$1.25
Volume
7,406
Avg. Vol
18,793
52-wk High
$5.70
52-wk Low
$1.00

Chart for

About

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer. The Company's product pipeline includes Therapeutic (MVT-5873),... (more)
No analyst recommendations are available for .

Overall

Beta: 1.36
Market Cap(Mil.): $11.75
Shares Outstanding(Mil.): 18.63
Dividend: --
Yield (%): --

Financials

  MBVX.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -3.99 -- --
ROI: -494.67 1.57 14.38
ROE: -2,287.18 2.43 16.07

BRIEF-Mabvax Therapeutics Updates On SEC Investigation, Accounting Discrepancies

* MABVAX THERAPEUTICS SAYS IN LIGHT OF SEC INVESTIGATION, UNABLE TO FILE FORM 10-Q FOR QUARTER ENDED MARCH 31, 2018 AT THIS TIME - SEC FILING

21 May 2018

BRIEF-Mabvax Therapeutics Holdings Inc Files For Non-Timely 10-Q

* MABVAX THERAPEUTICS HOLDINGS INC FILES FOR NON-TIMELY 10-Q - SEC FILING Source http://bit.ly/2ICIjF1 Further company coverage:

14 May 2018

BRIEF-MabVax Therapeutics Regains Compliance With NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement

* MABVAX THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ'S $1.00 MINIMUM BID PRICE MAINTENANCE REQUIREMENT Source text for Eikon: Further company coverage:

06 Mar 2018

BRIEF-Mabvax Therapeutics Reports Positive Safety Results From Initial Cohort Of MVT-1075

* MABVAX THERAPEUTICS REPORTS POSITIVE SAFETY RESULTS FROM INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS

28 Feb 2018

BRIEF-MabVax Therapeutics Says Reverse Stock Split Is Scheduled To Be Effective With Opening Of Trading On Feb 16

* MABVAX THERAPEUTICS SCHEDULES PREVIOUSLY ANNOUNCED 1-FOR-3 REVERSE STOCK SPLIT TO REGAIN COMPLIANCE WITH NASDAQ'S $1.00 MINIMUM BID PRICE MAINTENANCE REQUIREMENT

15 Feb 2018

BRIEF-Barry Honig Reports 4.99 Pct Stake In MabVax Therapeutics

* BARRY HONIG REPORTS 4.99 PERCENT STAKE IN MABVAX THERAPEUTICS HOLDINGS INC AS OF FEBRUARY 12, 2018 - SEC FILING‍​

13 Feb 2018

BRIEF-John Stetson Reports 4.99 Pct Stake In Mabvax Therapeutics Holdings

* JOHN STETSON REPORTS 4.99 PERCENT STAKE IN MABVAX THERAPEUTICS HOLDINGS INC AS OF FEBRUARY 12 - SEC FILING Source text: (http://bit.ly/2EoGXsh) Further company coverage:

12 Feb 2018

BRIEF-MabVax Therapeutics Announces Positive Interim Data From Trial of MVT-5873

* MABVAX THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FROM EXPANDED COHORT IN PHASE 1 TRIAL EVALUATING MVT-5873 IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY IN PANCREATIC CANCER

12 Feb 2018

BRIEF-Mabvax Therapeutics Holdings Provides Business Strategy Update

* MABVAX THERAPEUTICS HOLDINGS, INC. PROVIDES BUSINESS STRATEGY UPDATE

16 Jan 2018

BRIEF-MabVax Therapeutics Files For Resale Of 16.6 Mln Shares Of Co's Common Stock

* MABVAX THERAPEUTICS HOLDINGS INC FILES FOR RESALE OF 16.6 MILLION SHARES OF CO'S COMMON STOCK BY CERTAIN OF CO'S STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2of4wAj) Further company coverage:

15 Dec 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF76.16 -0.52
Roche Holding Ltd. (ROG.S) CHF219.25 -4.65
Roche Holding Ltd. (RO.S) CHF223.40 -5.40
Merck & Co., Inc. (MRK.N) $59.17 +0.72
Bayer AG (BAYGn.DE) €102.74 -2.30
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €66.23 -0.14
Eli Lilly And Co (LLY.N) $82.68 +0.46
Abbott Laboratories (ABT.N) $61.84 +0.45
Amgen, Inc. (AMGN.OQ) $179.94 +1.58

Earnings vs. Estimates